🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This morning our CEO Dr. Len Schleifer joined CNBC’s Squawk Box to discuss American biotech innovation, potential pharma tariffs and ways to ensure patients have access to important new medicines.

Regeneron CEO Len Schleifer on CNBC: The biotech/pharma sector should be seen as the "health defense industry" vital for global wellbeing. To sustain innovation, it needs proper support. cnb.cx/4iQSkfV

The U.S. FDA accepted for Priority Review our application to expand indications and dosing options for our medicine for certain #RetinalDiseases. More here: bit.ly/3ErbN7K

Exciting news! Our medicine for #ChronicSpontaneousUrticaria (CSU) is now FDA-approved. This helps fulfill an unmet need for the more than 300,000 eligible people living with this condition in the U.S. CC: @Sanofi

Sharing an update on our supplemental Biologics License Application in ophthalmology. Read more here: bit.ly/4lE4eLF

📣 We’re announcing a new agreement with FUJIFILM Diosynth Biotechnologies in North Carolina for the manufacturing of our industry-leading biologic medicines, bringing our ongoing investments in the U.S. to more than $7B.  Read more here bit.ly/43ZjtbO

We’re proud of our pioneering advancements in #ophthalmology and collaborative approach to supporting the #retinal community. Learn more about our deep-rooted history and approach to scientific innovation in our new Eye on the Experts video series: bit.ly/44ath2U

Next week at #ARVO2025, we’re presenting our latest research in #ophthalmology, including early insights on the real-world impact of our medicine for certain retinal diseases. Learn more about our presentations here: bit.ly/3Gs0woq

The European Commission has approved our medicine to treat relapsed/refractory #multiplemyeloma after at least three prior therapies. This is our second approved blood cancer medicine, reinforcing our commitment to transforming cancer care for those who need it most.

Today, we announced our first quarter 2025 financial and operating results, detailing continued momentum across our commercial portfolio and investigational medicines. Read more bit.ly/3Gxb1Xw

In 2024, we saw significant progress across our pipeline and portfolio. Hear from our co-founders, Len Schleifer and George Yancopoulos, as they reflect on last year’s progress, and visit our Year-in-Review (for investor audiences) to learn more: bit.ly/4jM6E9p

📣 At #ATS2025, the data we’re presenting have one shared goal: advance the science in respiratory diseases like #COPD and #asthma in a broad population of patients. Learn more about the latest scientific innovations we’ll share ⬇️  CC: @Sanofi

At #ASCO25, we’ll be sharing new insights and updates from our oncology and hematology research, including the latest investigational data from key skin and blood cancer programs. Click through below and read our press release: bit.ly/3YoMQRl

Today, a federal jury found that Amgen’s anticompetitive activities prevented Regeneron from competing on a level playing field and unfairly denied patients access to its PCSK9 treatment. This verdict is critical to protecting biotech innovation and patient access to treatments.

📣Today we announced that we intend to acquire 23andMe with plans to maintain their consumer genetics business and advance our shared goal of improving human health and wellness. bit.ly/43gI75D

Yesterday we announced our plans to acquire 23andMe. We’re excited to strengthen our leadership in genetics-guided research and prioritize the privacy, security and ethical use of this data. For those just getting to know Regeneron, here’s more about who we are:

At #ASCO25, we’re presenting research exploring investigational combinations in earlier lines of treatment for relapsed/refractory (R/R) #multiplemyeloma (MM). Learn more about our results in this difficult-to-treat #bloodcancer. bit.ly/43aqVzZ

We’re announcing results from two Phase 3 trials for our investigational #COPD medicine, a complex chronic respiratory disease. Learn more about the data ⤵️ cc: @Sanofi

At Regeneron, we strive to translate science into medicine for people impacted by cancer around the world. Hear from two of our leaders, Justin Holko and Txema Sanz, about how we’re expanding our global presence with this goal in mind. Watch the full video.

At #ASCO25, we presented detailed results from our Phase 3 trial investigating our immunotherapy as adjuvant treatment in high-risk #CSCC, also published in NEJM. Read more here: bit.ly/452Rx7p